NASDAQ:ACON Aclarion Q3 2026 Earnings Results & Report $1.64 -0.11 (-6.29%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Aclarion beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.94 versus the -$1.15 consensus estimate, while revenue of $33.73 thousand topped the $32 thousand estimate by $1.73 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call7:00 AM ET Aclarion EPS ResultsActual EPS-$0.94Consensus EPS -$1.15Beat/MissBeat by +$0.21One Year Ago EPSN/AEPS Beat Rate3 of last 6 quartersAclarion Revenue ResultsActual Revenue$33.73 thousandExpected Revenue$32 thousandBeat/MissBeat by +$1.73 thousandYoY Revenue GrowthN/AUpcoming EarningsAclarion's Q4 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Aclarion Q3 2026 Earnings FAQ Did Aclarion beat earnings estimates for Q3 2026? Aclarion (NASDAQ:ACON) reported earnings of -$0.94 per share for Q3 2026, beating the consensus estimate of -$1.15. The report was announced on Thursday, November 5, 2026. What was Aclarion's revenue for Q3 2026? Aclarion reported revenue of $33.73 thousand for Q3 2026, against a consensus estimate of $32 thousand. When is Aclarion's next earnings date? Aclarion's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aclarion on the company's earnings history page. Aclarion Earnings HeadlinesReviewing Aclarion (NASDAQ:ACON) & Schrodinger (NASDAQ:SDGR)November 2, 2026 | americanbankingnews.comAclarion Reports 85% Q3 Scan Volume Growth, Expands CLARITY Trial and Highlights New European Spine Journal PublicationOctober 20, 2026 | quiverquant.comQMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 10 at 1:00 AM | Behind the Markets (Ad)Aclarion to Present at the 20th Annual LD Micro Main EventOctober 13, 2026 | globenewswire.comAclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On TrackOctober 8, 2026 | rttnews.comAclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentOctober 8, 2026 | globenewswire.comSee More Aclarion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email. Email Address About AclarionAclarion (NASDAQ:ACON) is a medical technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops data-driven tools intended to help physicians identify the spinal discs most likely to be contributing to a patient’s pain and support more informed treatment decisions. Its principal product is Nociscan, a cloud-based software platform that analyzes magnetic resonance spectroscopy data from the spine. Using proprietary algorithms and chemical biomarkers associated with disc degeneration, Nociscan is designed to provide information about disc health and help distinguish potentially painful discs from discs that may not be the primary source of symptoms. Aclarion’s technology is intended for use by spine specialists, radiologists and other healthcare providers as an adjunct to conventional imaging and clinical evaluation. The company has pursued adoption of its platform in the United States and international markets, although availability and use may vary based on regulatory and commercial conditions.View Aclarion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
